Global Regenerative Therapies Market, 2016 to 2022
Persistence Market Research
Global Regenerative Therapies Market to
reach US$ 18,429.8 Mn by 2022: Persistence
Market Research
Persistence Market Research
1
Global Regenerative Therapies Market, 2016 to 2022
Persistence Market Research Released New Market Report According to a new market report
published by Persistence Market Research 'Global Market Study on Regenerative
Therapies: Asia Pacific & Japan to Witness Highest Growth by 2022’, the global
regenerative therapies market is expected to expand at a CAGR of 20.0% during the forecast
period 2016 - 2022.
The market is segmented based on tissue type, application type, end user type, and region.
On the basis of tissue type, the overall market has been segmented into allografts,
xenografts, and alloplasts. On the basis of application type, the market has been segmented
into soft tissue repair, cardiovascular, dental, orthopedic, CNS disease treatment, and
others, which include diabetes, autonomous diseases, ocular, and oncology. On the basis of
end-user, the market has been segmented into hospitals, ambulatory surgical centers, and
educational institutes. By tissue type, the allografts segment is expected to remain the
largest segment, registering the highest CAGR of 22.8% in terms of value, over the forecast
period. The long-term effectiveness of the treatment and higher its higher biocompatibility
with the patient is expected to contribute to the rise in its popularity over the forecast
period. The allografts tissue type segment is expected to reach a market value of US$
11,633.2 Mn by the end of the forecast period. The allografts tissue is also expected to
emerge as the most preferred tissue type for both patients and physicians, globally, over the
forecast period. The second most popular tissue type choice is xenografts, which are
basically prepared by using various animal tissues.
On the basis of the application type, the market has been segmented into soft tissue repair,
cardiovascular, dental, orthopedic, CNS disease treatment, and others (which includes
diabetes, autonomous diseases, ocular, and oncology). Currently, a majority of the patients
and surgeons globally prefer regenerative therapies for orthopedic, soft tissue repair, and
cardiovascular problems.
On the basis of the end user segment type, the market has been segmented into hospitals,
ambulatory surgical centers, and educational institutes. Currently, hospitals are the most
preferred option for patients globally.
On the basis of region, the market has been segmented into North America, Latin America,
Europe, Asia Pacific & Japan, and the MEA regions.
Persistence Market Research
2
Global Regenerative Therapies Market, 2016 to 2022
Rising per capita healthcare expenditure and contribution to GDP, increasing funding &
government support for the development of regenerative therapies, as well as surge in
incidences of chronic diseases are major factors driving the growth of the global
regenerative therapies market currently.
Other trends driving the market growth include industry maturation, advancements in
technology, and increasing demand for long-term results and shorter-time therapeutic
procedures by patients. However, the market is expected to observe regulatory reestablishment with an increase in regenerative procedures and standardization of therapies
over the forecast period.
The absence of standard regulations and legislations is leading to the invasion of many local
players in both the developed and emerging regions. Moreover, high gestation period and
time-to-market due to lengthy clinical trials, a large number of product recall within a short
span post-approval, and lack of financial-backing by smaller firms are among the major
factors hampering the growth of regenerative therapies market currently.
Request Sample Report: http://www.persistencemarketresearch.com/samples/10598
This report assesses trends driving each market segment and offers analysis and insights
about the potential of regenerative therapies in specific regions. North America market is
estimated to dominate the overall regenerative therapies market, accounting for a
maximum value share of the global market by the end of 2016. By 2022, North America and
Europe markets are expected to account for over three-fourth revenue share of the global
regenerative therapies market. In terms of value, North America is estimated to be the
dominant market, expanding at a CAGR of 19.7% over the forecast period.
View Detail Report With TOC: http://www.persistencemarketresearch.com/marketresearch/regenerative-therapies-market.asp
Persistence Market Research
3
Global Regenerative Therapies Market, 2016 to 2022
Some key companies covered in this report include Acelity L.P. Inc., Mesoblast Ltd., Nuo
Therapeutics, Inc. (Cytomedix), Astellas Pharma US, Inc., Organovo Holdings Inc., Orgenesis
Inc., Sanofi, Athersys, Inc., Shire Pharmaceuticals Limited, and Cytori Therapeutics Inc.
These companies are primarily focused on enhancing their product portfolio through R&D
and on the introduction of innovative and cost-effective regenerative therapies in order to
gain higher market share and to strengthen their respective position in the global
regenerative therapies market.
Market History:
Regenerative therapies entail the application of specific types of cells or cell products for
diseased tissues or organs, which would ultimately help restore tissue and organ function. It
also involves the possibility of growing tissues and organs in the laboratory and safely
implanting them when the body cannot heal itself.
The global regenerative therapies market has been estimated to be valued at US$ 5,286.2
Mn by the end of 2015, and is projected to witness stable growth across all global regions,
which is attributed to the rising demand for fulfilling unmet clinical needs for longer
sustainability and faster outcome treatments within a shorter time span.
The prime growth driver for the global regenerative therapies market is deficiency in
therapeutic requirements. Currently, government support for treatment of various diseases
is increasing globally, through the formation and adoption of supportive legislative and
policy initiatives, which also include sizeable investments in regenerative therapies for
creating centers of excellence, research networks, manufacturing infrastructure, and
commercialization centers, among others. Furthermore, increasing demand for tissue-cell
and stem cell research technologies as well as the products developed from them, which are
used for treating various chronic diseases having no permanent cure, are the other
important factors driving growth of the global regenerative therapies market currently.
However, an ongoing trend that has been witnessed in the market is the increasing shift of
companies from manufacturing of synthetic drugs to evaluating opportunities for generating
medicines from an individual’s own tissues and stem cells.
Being at an early stage of commercialization, the regenerative therapies market exhibits
lucrative investment opportunities created by government, regional governing bodies, and
private companies. Regenerative therapies find application in the treatment of various
Persistence Market Research
4
Global Regenerative Therapies Market, 2016 to 2022
diseases, such as wound repair, orthopedic diseases, neurological diseases, cardiovascular
diseases, autoimmune disorders, ocular diseases, and other rare diseases. The major reason
why these therapies are used in the various treatments is because they facilitate long-term
effectiveness and safer results among various diseased patients.
Increasing regulatory harmonization to accelerate pace of product approvals is rapidly
becoming a necessity for regenerative therapy players all over the world.
Globally, Asia Pacific market is expected to expand at the strongest CAGR in the global
market for regenerative therapies throughout the forecast period in terms of revenue.
Growing regulatory harmonization and the fact that the local manufacturers are able to meet
international standards maintained by the leading companies are among the major factors
anticipated to lead to standardization of the regenerative therapies market in the region.
Allografts tissue type segment is currently dominating the market in the region in terms of
the tissue’s biocompatibility with patients. In addition, increasing contract research
outsourcing in the field of regenerative therapies in countries such as Singapore, Thailand,
and South Korea, which is primarily attributed to the availability of highly-skilled local talent
pool and presence of highly-sophisticated research facilities and storage infrastructure (e.g.
stem cell banks) in these countries, is expected to boost the market growth in the APAC
region. Japanese government has been promoting liberalization of rules on regulations,
which could expedite the route to market timeline for regenerative therapies. Most major
governments in the countries in Asia Pacific have been promising positive support for
regenerative therapies, a fact which could help in organ regeneration, tissue re-engineering,
etc. Celebrity support is another crucial factor promoting growth of the regenerative
therapies market in these countries. However, cost issues, lengthy clinical trials, and lack of
standard guidelines options are factors expected to slightly hamper growth of the market.
Europe is the second-most profitable destination for regenerative therapies currently.
Collaborative efforts help minimizing probabilistic abandonment of clinical trials and raise
involvement of SMEs in drug development, which is expected to become a norm in the
region over the next few years. Unique medicinal fields, such as nephrology and Chronic
Obstructive Pulmonary Diseases (COPD), are repeatedly being studied by researchers from
Europe for carrying out breakthrough evidence-based treatments in the region. Thus, the
market in the region is expected to expand at a stable CAGR over the forecast period in
terms of revenue. Major companies based in Europe are seeking expanding their presence
Persistence Market Research
5
Global Regenerative Therapies Market, 2016 to 2022
outside the region in order to be able to efficiently meet growing global demand for its
products.
North America is a prime regional market currently, accounting for over 50% of the overall
regenerative therapies market in terms of revenue, and the trend is expected to continue
over the forecast period as well. However, researchers are working on the development of
new clinical infrastructure in the field of regenerative stem cell therapies, which is still in the
initial stages of development, with a failure rate of 80% in the initiation phases. Moreover,
there is an increasing penetration of tissue banks in North America. In these tissue banks,
articular cartilage has been observed as a particularly good target for allograft
transplantation. In addition, Canadian legislation for regenerative therapies is more
supportive than in the U.S. Presently, the Biologics and Genetic Therapy Directorate (BGTD)
of the Health Products and Food Branch of Health Canada is reviewing the guidelines written
in 2000 for safety of cells, tissue, and organs for transplantation. Legislative support and
regulatory harmonization are the two major factors expected to help simplify the clinical trial
infrastructure in the region.
Globally, the Asia Pacific market is expected to expand at the highest CAGR in terms of
value, followed by Europe and North America. The Middle East & Africa market accounts for
a nominal value share of the overall regenerative therapies market currently, owing to the
absence of adequate regulations and inability of the various governments in the region to
enforce regulations, which in turn has been promoting growth of untested and illegitimate
regenerative therapeutic practices in South Africa in the field of stem-cell applications.
Besides, cultural superstitions and failure to understand the working mechanism are factors
that could delay entry of mainstream regenerative therapies in the country in the long run.
Key market participants covered in the report include Acelity L.P. Inc., Mesoblast Ltd., Nuo
Therapeutics, Inc. (Cytomedix), Astellas Pharma US, Inc., Organovo Holdings Inc., Orgenesis
Inc., Sanofi, Athersys, Inc., Shire Pharmaceuticals Limited, and Cytori Therapeutics Inc,.
Persistence Market Research
6
Global Regenerative Therapies Market, 2016 to 2022
Follow us on Linkedin: https://www.linkedin.com/company/persistence-market-research-&consulting
About Us:
Persistence Market Research (PMR) is a full-service market intelligence firm specializing in syndicated
research, custom research, and consulting services. PMR boasts market research expertise across the
Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages,
Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The
company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data
that precisely corresponds to clients’ business needs.
Contact Us:
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA - Canada Toll Free: 800-961-0353
Email: [email protected]
Web: http://www.persistencemarketresearch.com
Persistence Market Research
7